Article

Poll: Were you warned about side effects?

Author(s):

Staff

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Related Content
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
July 31st 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.
The Importance of Spotting Endometrial Cancer
July 31st 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of kidneys.
July 31st 2025

July GU Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
As July concludes, new treatments offer advances across kidney and bladder cancer, with breakthroughs in personalized vaccines and non-surgical therapies.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
July 31st 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of blood cells.
July 31st 2025

Venclexta Treatment Combo is Being Reviewed by FDA For CLL

Ryan Scott
AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic lymphocytic leukemia.
Image of lungs.
July 31st 2025

July Lung Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.